Abstract
Background:
Despite the high prevalence of depression in the United States, 10 few studies have identified which adverse effects (AEs) patients are willing or unwilling to tolerate when receiving antidepressants.
Objective:
The aim of this study was to identify reasons for discontinuation10 and noncompliance with antidepressant medications, the impact of AEs on compliance and quality of life (assessed using impact of AEs on activities of daily living), and patients' suggestions for improving their medication, using a patient survey.
Methods:
Patients aged 18 to 65 years with mild to severe depression were 10 randomly selected by their physicians to be sent an invitation to complete the 42-question survey. Three hundred physicians nationwide assessed the severity of depression and symptoms of anxiety in each respondent, using their judgment. Patients were asked specific questions to assess reasons for discontinuation/noncompliance. Patients were also asked to rate AEs based on how difficult they were to “live with,” and what 2 aspects of their antidepressant medication they would change if they could.
Results:
In a separate, concurrent study, physicians classified 175 (50%) abdResults:0 mildly to moderately depressed and 84 (24%) as severely depressed. Ninety-one respondents (26%) were classified as having symptoms of anxiety. Two hundred seven patients (60%) indicated they had discontinued treatment with an antidepressant agent at some point in their lives, the most common reason for which was lack of efficacy (92 patients [44%]). Of the 344 patients currently being treated with an antidepressant, 75 (22%) reported noncompliance. The most common reasons for noncompliance were “have trouble remembering to take it” (19/44 patients [43%]), “gained a lot of weight” (11/41 [27%]), “unable to have an orgasm” (8/40 [20%]), and “lost interest in sex” (8/41 [20%]). The 4 AEs patients expressed as “extremely difficult to live with” were “weight gain” (104 patients [31%]), “unable to have erection” (83 [25%]), “difficulty reaching orgasm” (80 [24%]), and “tired during the day/no energy” (69 patients [21%]). The 3 most frequently cited improvements patients (n = 327) would make to their medications were better efficacy (176 patients [54%]) and eliminating AEs related to sexual desire and weight gain (112 [34%] and 105 [32%] patients, respectively).
Conclusions:
The findings of this survey of patients with mild to severe10 depression suggest that compliance, and hence efficacy, can be promoted by (1) understanding what patients expect and desire from the antidepressants they are prescribed and (2) prescribing antidepressants associated with low rates of weight gain, sexual dysfunction, or tiredness.
Key words: noncompliance, antidepressants, tolerability, discontinuation
Full Text
The Full Text of this article is available as a PDF (589.4 KB).
Footnotes
This work was presented in poster form at the 154th Annual Meeting of the American Psychiatric Association, May 5–10, 2001, New Orleans, Louisiana.
References
- 1.Patient compliance in depression. Based on a presentation by James Jefferson, MD. Am J Manag Care. 2000;6(Suppl 2):S31–S38. [PubMed] [Google Scholar]
- 2.Greenberg P.E., Stiglin L.E., Finkelstein S.N., Berndt E.R. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54:405–418. [PubMed] [Google Scholar]
- 3.Murphy S.I. National Vital Statistics Reports. 2000:48. [PubMed] [Google Scholar]
- 4.Lingam R., Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105:164–172. doi: 10.1034/j.1600-0447.2002.1r084.x. [DOI] [PubMed] [Google Scholar]
- 5.Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49:196–201. doi: 10.1176/ps.49.2.196. [DOI] [PubMed] [Google Scholar]
- 6.Demyttenaere K., Enzlin P., Dewe W. Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001;62(Suppl 22):30–33. [PubMed] [Google Scholar]
- 7.Delgado P.L. Approaches to the enhancement of patient adherence to antidepressant medication treatment. J Clin Psychiatry. 2000;61(Suppl 2):6–9. [PubMed] [Google Scholar]
- 8.Frank E. Enhancing patient outcomes: Treatment adherence. J Clin Psychiatry. 1997;58(Suppl 1):11–14. [PubMed] [Google Scholar]
- 9.Demyttenaere K. Compliance and acceptance in antidepressant treatment. Int J Psychol Clin Pract. 2001;5:529–535. doi: 10.1080/13651500152048423. [DOI] [PubMed] [Google Scholar]
- 10.Zajecka J.M. Clinical issues in long-term treatment with antidepressants. J Clin Psychiatry. 2000;61(Suppl 2):20–25. [PubMed] [Google Scholar]
- 11.Tai-Seale M., Croghan T.W., Obenchain R. Determinants of antidepressant treatment compliance: Implications for policy. Med Care Res Rev. 2000;57:491–512. doi: 10.1177/107755870005700405. [DOI] [PubMed] [Google Scholar]
- 12.Bull S.A., Hunkeler E.M., Lee J.Y. Discontinuing or switching selective serotoninreuptake inhibitors. Ann Pharmacother. 2002;36:578–584. doi: 10.1345/aph.1A254. [DOI] [PubMed] [Google Scholar]
- 13.Code of Federal Regulations, Food and Drug Administration, 21. 1998. [Google Scholar]
- 14.Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296–1310. doi: 10.1016/s0149-2918(01)80109-0. [DOI] [PubMed] [Google Scholar]
- 15.Ashton A.K., Rosen R.C. Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Marital Ther. 1998;24:191–192. doi: 10.1080/00926239808404932. [DOI] [PubMed] [Google Scholar]
- 16.Hirschfeld R., Rajagopalan R., Watson C.B. 41st Annual Meeting of the National Institutes of Health New Clinical Drug Evaluation Unit. 2001. Bupropion SR, paroxetine, and sertraline: Onset and duration of adverse events. Poster presented at. Phoenix, Ariz. Phoenix, Ariz. [Google Scholar]
- 17.Fava M., Judge R., Hoog S.L. Fluoxetine versus sertraline and paroxetine in major depressive disorder: Changes in weight with long-term treatment. J Clin Psychiatry. 2000;61:863–867. doi: 10.4088/jcp.v61n1109. [DOI] [PubMed] [Google Scholar]
- 18.Weihs K.L., Houser T.L., Batey S.R. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51:753–761. doi: 10.1016/s0006-3223(01)01317-8. [DOI] [PubMed] [Google Scholar]
- 19.Mundt J.C., Clarke G.N., Burroughs D. Effectiveness of antidepressant pharmacotherapy: The impact of medication compliance and patient education. Depress Anxiety. 2001;13:1–10. doi: 10.1002/1520-6394(2001)13:1<1::aid-da1>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
- 20.Weintraub M. Intelligent noncompliance with special emphasis on the elderly. Contemp Pharm Pract. 1981;4:8–11. [PubMed] [Google Scholar]
- 21.Bultman D.C., Svarstad B.L. Effects of physician communication style on client medication beliefs and adherence with antidepressant treatment. Patient Educ Couns. 2000;40:173–185. doi: 10.1016/s0738-3991(99)00083-x. [DOI] [PubMed] [Google Scholar]